OUTSOURCING
Early-Phase Whole-Body PK
Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.
What Is Causing Limited Bioavailability
Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.
Biopharma Resilience: Bionova Scientific Talks Capacity, Speed, And Agility
Bionova Scientific shares how a CDMO can offer biopharma companies the flexible capacity they need to meet the growing needs for medicines today and in the future.
Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy
One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remai...
Selecting The Right CMO For Your Gene Therapy
Find out what criteria makes a great CMO partner and how to know if it is the right one for your gene therapy.